WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Palace scores 4 goals in opening 31 minutes on way to 5Satellite image analysis: Iranian attack damaged Israeli air baseSarah Ferguson remembers the late Queen Elizabeth with a sweet message on her birthdayColton Cowser and Jordan Westburg hit backInside the Los Angeles highway houses: SkyBridgerton's Nicola Coughlan stuns in glittering black gown as she holds hands with coAnother race, another victory for Red Bull's Max Verstappen at Chinese GPJosh Naylor's 3 RBIs sends Guardians to 6Jesús Sánchez hits a long solo homer as the Marlins beat the Cubs 6Casey Mize throws 6 shutout innings for 1st win since 2021 as Tigers beat Twins 6
2.4968s , 4667.1328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Circuit news portal